Medically Reviewed by Dr. Tom Biernacki, DPM, FACFAS | Functional Medicine & Preventive Cardiology | Updated May 2025
Quick Answer
ApoB (Apolipoprotein B) is a protein on every atherogenic lipoprotein particle in your blood — LDL, VLDL, IDL, and Lp(a). Each particle carries exactly one ApoB molecule, so ApoB directly measures the number of atherogenic particles in your bloodstream. Most cardiologists and longevity physicians consider ApoB the gold-standard cardiovascular risk marker, superior to LDL cholesterol. Optimal ApoB for longevity: below 60 mg/dL. The standard lab cutoff of <100 mg/dL is minimum acceptable, not optimal.
In This Article
I have a patient I will call Mark — 52 years old, no symptoms, exercises regularly, eats reasonably well. His annual physical was unremarkable. Total cholesterol 195, LDL 118, HDL 52, triglycerides 120. His internist told him his cholesterol was “excellent.” Mark came to my practice for a longevity workup, and I ordered an ApoB. It came back at 108 mg/dL — a level associated with a 40% higher 10-year MACE risk compared to someone at 60 mg/dL, even with the same LDL. Mark had been walking around with a meaningful cardiovascular risk burden that his standard lipid panel had entirely missed. This is not an unusual story. It is the norm.
The scientific consensus has shifted decisively toward ApoB as the primary lipid marker for cardiovascular risk. The European Atherosclerosis Society, the Canadian Cardiovascular Society, and a growing plurality of American preventive cardiologists now recommend ApoB as the primary lipid treatment target. Yet most primary care panels still do not include it by default. If you have not had an ApoB measured, you do not know your true cardiovascular risk.
What Is ApoB?
Apolipoprotein B is a large structural protein that forms the backbone of every atherogenic lipoprotein particle circulating in your blood. Every LDL particle has one ApoB molecule. Every VLDL particle has one ApoB molecule. Every IDL and Lp(a) particle has one ApoB molecule. HDL particles do not carry ApoB — they carry ApoA-I. This one-to-one relationship between ApoB and atherogenic particles is what makes ApoB so valuable: it directly counts the number of particles capable of penetrating the arterial wall and initiating the atherosclerotic cascade.
Atherosclerosis begins when ApoB-containing lipoprotein particles cross the endothelium into the arterial intima. Once retained there, they undergo oxidation and trigger an inflammatory response that eventually becomes a plaque. The rate of this process is directly proportional to the number of ApoB particles — their concentration, their residence time in the arterial wall, and the inflammatory environment they encounter. Reducing ApoB reduces the fundamental substrate for atherosclerosis.
Standard LDL cholesterol (LDL-C) measures the total amount of cholesterol transported inside LDL particles — not the number of particles. Two people can have identical LDL-C values while having dramatically different particle numbers, because individual LDL particles vary considerably in the amount of cholesterol they carry. A person with many small, cholesterol-poor LDL particles will have a high particle count (high ApoB) but a deceptively low LDL-C. This is the “LDL discordance” problem, and it is far more common in people with insulin resistance, metabolic syndrome, or elevated triglycerides.
Why ApoB Is Superior to LDL-C for Predicting Cardiovascular Risk
The superiority of ApoB over LDL-C as a cardiovascular risk predictor is now supported by multiple large prospective studies and meta-analyses. The key evidence:
- INTERHEART study (52 countries, 15,000 patients): ApoB/ApoA-I ratio was the strongest lipid predictor of acute MI risk across all populations studied — stronger than LDL-C, HDL-C, or total cholesterol (PMID: 15364185).
- AMORIS prospective cohort: In 98,722 subjects followed for 8 years, ApoB predicted future MI significantly better than LDL-C, especially in subjects with triglycerides above 1.5 mmol/L (PMID: 11502349).
- Copenhagen City Heart Study: Found ApoB to be a stronger MI predictor than non-HDL cholesterol, especially in women (PMID: 18305148).
- Mendelian randomization studies: Genetic studies that reduce ApoB-containing lipoproteins — regardless of the mechanism — consistently show proportional reductions in cardiovascular events. This causal relationship holds for ApoB but not consistently for LDL-C in isolation (PMID: 33831559).
A 2021 analysis in the European Heart Journal that examined 446,000 participants found that when LDL-C and ApoB disagreed — which happened in approximately 25% of cases — ApoB was the more accurate predictor of cardiovascular outcomes in virtually every subgroup (PMID: 33831559).
Key Takeaway: LDL-C tells you how much cholesterol is in your LDL particles. ApoB tells you how many atherogenic particles are in your blood. In 25% of people — typically those with insulin resistance, high triglycerides, or metabolic syndrome — these two numbers point in different directions. In every major study comparing them, ApoB wins.
What Is a Good ApoB Level? (Optimal vs. Standard Targets)
Laboratory reference ranges for ApoB were established to reflect population averages — not optimal longevity targets. This distinction matters enormously in practice. Here is how I think about ApoB targets in my functional medicine practice:
| ApoB Level | Cardiovascular Risk Context | Clinical Interpretation |
|---|---|---|
| <60 mg/dL | Longevity-optimal | The level seen in populations with very low ASCVD incidence. My personal target for low-risk, optimizing patients. |
| 60-80 mg/dL | Low risk | Acceptable for most low-risk individuals. Associated with modest atherosclerotic progression. |
| 80-100 mg/dL | Moderate risk | Standard guidelines call this “borderline.” In my practice, this range warrants intervention discussion. |
| 100-130 mg/dL | High risk | Most guidelines recommend pharmacological consideration at this level combined with risk factors. |
| >130 mg/dL | Very high risk | Strong indication for statin or PCSK9 inhibitor therapy regardless of LDL-C. |
Context matters significantly. A 35-year-old with an ApoB of 85 mg/dL and no risk factors is in a different clinical situation than a 55-year-old with hypertension, insulin resistance, and a family history of MI at the same level. Absolute risk calculators that incorporate ApoB — rather than just LDL-C — provide the most accurate 10-year event risk estimates.
For patients who have already had a cardiovascular event (secondary prevention), the targets are more aggressive. The 2019 ESC/EAS guidelines recommend ApoB below 65 mg/dL for very high-risk patients and below 55 mg/dL for those with recurrent events. These are evidence-based targets with Mendelian randomization support — lower is causally better.
What Raises Your ApoB
Understanding what drives ApoB up is as important as knowing what brings it down. The major contributors:
Insulin Resistance and Metabolic Syndrome
Insulin resistance is the most common driver of elevated ApoB in metabolically active patients. When insulin signaling fails in the liver, hepatic VLDL production increases dramatically — each VLDL particle carries one ApoB molecule. These VLDL particles are converted downstream to LDL, producing the classic “metabolic dyslipidemia” pattern: high triglycerides, low HDL, and elevated ApoB with often-normal or only modestly elevated LDL-C. This pattern is the one most commonly missed by standard lipid panels and most commonly detected by ApoB measurement.
Dietary Saturated and Trans Fat
Saturated fatty acids (particularly lauric, myristic, and palmitic acids) upregulate hepatic LDL receptor downregulation and increase LDL particle production. Trans fats are even more potent — they simultaneously raise LDL particle number and suppress HDL synthesis. The relationship between dietary saturated fat and ApoB is not universal (individual response varies based on genetics and baseline insulin sensitivity), but it is real and clinically significant in a meaningful minority of patients.
Familial Hypercholesterolemia (FH)
FH is an autosomal dominant condition affecting approximately 1 in 250 people, caused by loss-of-function mutations in the LDL receptor gene (LDLR), ApoB itself, or PCSK9. FH patients have chronically elevated ApoB from birth — often 150-200+ mg/dL — due to impaired LDL receptor-mediated clearance. Many patients with FH are undiagnosed because their LDL-C, while elevated, is sometimes attributed to diet. A family history of premature cardiovascular disease (MI or stroke before age 55 in a first-degree male relative, or before 65 in a female) warrants FH screening with ApoB measurement.
Hypothyroidism
Thyroid hormone upregulates LDL receptor expression. In hypothyroid states, LDL receptor activity falls, LDL clearance slows, and ApoB rises. This is why ApoB can improve dramatically with thyroid optimization — sometimes by 20-30% with T4 alone, without any lipid-specific intervention. In my practice, I always check thyroid function before attributing elevated ApoB to lifestyle or genetics.
Obstructive Sleep Apnea
Untreated OSA produces intermittent hypoxia that activates the sympathetic nervous system, drives hepatic lipogenesis, and raises VLDL production — all of which increase ApoB. Multiple studies have demonstrated ApoB reduction with effective CPAP therapy. If a patient has elevated ApoB with intact metabolic health and no dietary explanation, sleep apnea is on my differential.
How to Lower Your ApoB: Lifestyle, Diet, and Pharmacology
Reducing ApoB is the most evidence-based cardiovascular risk intervention available. Here is the evidence hierarchy:
1. Reverse Insulin Resistance First
For patients whose elevated ApoB is driven by metabolic syndrome (elevated triglycerides, low HDL, central adiposity, elevated fasting glucose), the primary intervention is metabolic — not lipid-specific. Weight loss, Zone 2 cardio, carbohydrate restriction, and sleep optimization can reduce ApoB by 20-40 mg/dL in patients with significant insulin resistance, often without any pharmacological intervention. I have patients who moved from ApoB 120 to 78 mg/dL through lifestyle alone over 6 months of structured metabolic work.
2. Dietary Interventions
The most evidence-based dietary approaches for ApoB reduction include replacing saturated fats with unsaturated fats (particularly olive oil and omega-3-rich foods), increasing soluble fiber (10-15g/day of psyllium husk or oat bran reduces ApoB by 5-10%), adding plant sterols (2g/day reduces LDL particle number by 8-15%), and reducing refined carbohydrates and added sugars (which drive VLDL and triglycerides). The Mediterranean and Portfolio diets have the strongest RCT evidence for ApoB reduction through diet alone.
3. Statins
High-intensity statins (rosuvastatin 20-40 mg, atorvastatin 40-80 mg) reduce ApoB by 35-55% by upregulating hepatic LDL receptor expression and reducing intracellular cholesterol synthesis. Statins are the most evidence-based ApoB-lowering pharmacological intervention available, with decades of RCT data and Mendelian randomization support for cardiovascular event reduction proportional to ApoB lowering. For patients with ApoB above 100 mg/dL and intermediate-to-high 10-year ASCVD risk, the risk-benefit calculation strongly favors pharmacological intervention alongside lifestyle.
4. Ezetimibe
Ezetimibe inhibits intestinal cholesterol absorption via NPC1L1 and reduces ApoB by an additional 15-20% on top of statin therapy. The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy reduced cardiovascular events proportionally to the achieved ApoB reduction (PMID: 26039521). It is generally well-tolerated, inexpensive, and my second-line add-on when statins alone do not achieve the target ApoB.
5. PCSK9 Inhibitors
Evolocumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies that block PCSK9, preventing LDL receptor degradation and dramatically increasing LDL clearance. They reduce ApoB by 50-70% on top of maximal statin therapy — the most potent non-interventional ApoB-lowering option available. The FOURIER and ODYSSEY OUTCOMES trials demonstrated significant cardiovascular event reduction. Currently indicated for FH and high-risk patients not at goal on maximal statin plus ezetimibe.
Important: ApoB targets should be individualized based on total cardiovascular risk, not just the ApoB number in isolation. A 40-year-old with an ApoB of 90 mg/dL and no risk factors has a different risk profile than a 60-year-old with diabetes, hypertension, and the same ApoB level. Always interpret ApoB in the context of a full cardiovascular risk assessment.
Frequently Asked Questions
Why does my doctor not test ApoB on my standard lipid panel?
Standard lipid panels were designed decades ago when LDL-C was the only measurable marker. ApoB requires an additional assay and adds cost — typically $10-$30 when ordered in the US. Many primary care physicians are not trained to interpret it or feel LDL-C is sufficient for their purposes. In functional medicine and preventive cardiology practices, ApoB has become standard. If your doctor does not offer it, you can request it specifically — it is a standard lab test available at all major reference labs. Some direct-to-consumer lab services (Quest, LabCorp, Let’s Get Checked) allow you to order it without a physician order.
Is ApoB the same as LDL particle number (LDL-P)?
They measure related but not identical things. LDL-P (measured by NMR spectroscopy, reported on tests like Boston Heart or LabCorp Lipoprotein Particle Panel) counts only LDL particles. ApoB counts all ApoB-containing particles — LDL, VLDL, IDL, and Lp(a). When triglycerides are elevated, ApoB will be higher than LDL-P would suggest because it captures VLDL particles as well. For most patients, ApoB and LDL-P correlate well. ApoB is generally preferred because it is cheaper, more widely available, and better standardized across laboratories.
Can I have a normal LDL but a high ApoB?
Yes — and this is clinically important. This pattern is called “ApoB-LDL discordance” and occurs most commonly in patients with insulin resistance, elevated triglycerides, metabolic syndrome, or type 2 diabetes. In discordant cases, the patient has many small, cholesterol-depleted LDL particles (high particle count, low LDL-C per particle). Their LDL-C looks acceptable but their atherogenic particle burden is significantly elevated. Studies consistently show that in discordant patients, ApoB predicts cardiovascular outcomes and LDL-C does not.
What is the difference between ApoB and Lp(a)?
Lp(a) is a specific atherogenic lipoprotein particle that carries one ApoB molecule plus an additional protein called apolipoprotein(a). ApoB measurement counts Lp(a) particles along with LDL, VLDL, and IDL particles. However, Lp(a) has unique pathological features — including thrombogenic and pro-inflammatory properties — that make it worth measuring separately. An ApoB test will not tell you your Lp(a) level; you need a specific Lp(a) assay. For a complete cardiovascular risk picture, I measure both ApoB and Lp(a) on every patient.
The Bottom Line
ApoB is the most actionable single number in the cardiovascular risk picture. It directly measures the atherogenic particle burden in your bloodstream — the fundamental driver of plaque formation — and it predicts cardiovascular events more accurately than LDL-C in virtually every head-to-head comparison. The science has been settled for over a decade. The clinical adoption is finally catching up. If you have never had your ApoB measured, you do not know your true cardiovascular risk. If your ApoB is above 100 mg/dL and your doctor is satisfied with your “normal” LDL-C, you are missing a critical piece of your health picture. Get the test. Know your number. Then work systematically — through lifestyle, diet, and pharmacology as needed — to drive it toward the <60 mg/dL range that longevity science supports as optimal.
Sources
- Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study). Lancet. 2004;364(9438):937-952. PMID: 15364185
- Walldius G, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study). Lancet. 2001;358(9298):2026-2033. PMID: 11502349
- Sniderman AD, et al. The causal exposure model of vascular disease: the case for revisiting the definition of atherogenic dyslipidaemia. European Heart Journal. 2021;42(34):3320-3326. PMID: 33831559
- Cannon CP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). New England Journal of Medicine. 2015;372(25):2387-2397. PMID: 26039521
- Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). New England Journal of Medicine. 2017;376(18):1713-1722. PMID: 28304224
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. PMID: 30586774
Ready to Know Your True Cardiovascular Risk?
We run a comprehensive ApoB-centered cardiovascular panel — including ApoB, Lp(a), oxidized LDL, hs-CRP, and advanced lipid fractionation — as part of our functional medicine longevity evaluation. Dr. Biernacki interprets these results in the context of your metabolic health, family history, and lifestyle to build an individualized cardiovascular risk reduction strategy.